Stream Link 1 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1678823&tp_key=49c8aa1154
Stream Link 6 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1678825&tp_key=0f91b4fc3c
This activity is part 2 of a 3-part webinar curriculum.
Program Description
Given the chronic nature of eosinophilic esophagitis (EoE), effective therapies are central to managing the condition, preventing complications, and improving patients' quality of life. Treatment goals for EoE include the resolution of symptoms and eosinophilic inflammation, maintenance of remission, and avoidance of potential complications. The expanding treatment landscape now includes biologics and oral therapies, and pharmacists will require knowledge of their efficacy and safety profiles to support treatment decision-making with patients. In light of new therapy approvals, staying up to date on treatment guidelines is crucial. This webinar will explore the treatment landscape of EoE. Participants will review key considerations for patient selection and eligibility according to guideline recommendations as well as strategies to optimize adherence and manage potential adverse effects.
Target audience: Retail pharmacists
Type of activity: Application
Release date: August 22, 2024
Expiration date: October 22, 2024
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Compare the pharmaceutics of oral therapies and their role in treating eosinophilic esophagitis (EoE)
- Examine the safety and efficacy data for new and emerging therapies in the management of EoE
- Apply clinical guidelines and evidence-based medicine to the standard of care for managing EoE
Caroline M. Sierra, PharmD
Associate Professor of Pharmacy Practice
Loma Linda University School of Pharmacy
Loma Linda, California
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-191-L01-P. The activity is available for CE credit through October 22, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Caroline M. Sierra, PharmD, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Adam C. Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms